C-DQSCKhondrion
mitochondrial disease, small molecule, sonlicromanol
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-DQSC
C-DQSCC-DQSCmitochondrial disease, small molecule, sonlicromanol
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
This is an open-label, multi-centre study in subjects with a genetically confirmed mitochondrial deoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A\>G mutation who completed study KH176-202. In the KH176-203 study subjects will be receiving KH176 100 mg BID or KH176 50 mg bid in die (BID) (as determined by the investigator based on safety / tolerability considerations) for a year, thereby ensuring continued treatment with KH176 after study KH176-202. A final follow-up visit is scheduled 4 weeks after the intake of the last dose of study medication for patients not rolling over into the compassionate use program. Primary safety data and secondary efficacy (endpoint) data will be monitored and reviewed every three months by an independent Data Safety Monitoring Board (DSMB) to evaluate potential risks and benefits.
This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms ("KHENERGYC").
Mitochondrial diseases, estimated prevalence 1 in 4,300 adults, is caused by pathogenic mutations in genes finally encoding for mitochondrial proteins of the various enzyme complexes of the OXPHOS. Among these mutations, the 3243A\>G nucleotide change in the mitochondrially encoded transfer RNALeu(UUR) leucine 1 gene (MT TL 1) is the most prevalent one. The OXPHOS dysfunction resulting from such mutations leads to increased production of reactive oxygen species (ROS), ultimately leading to irreversible oxidative damage of macromolecules, or to more selective and reversible redox modulation of cell signaling that may impact (adult) neurogenesis. Despite advances in the understanding of mitochondrial disorders, treatment options are extremely limited and, to date, largely supportive. Therefore, there is an urgent need for novel treatments. KH176, a new active pharmaceutical ingredient (API), is an orally bio-available small molecule under development for the treatment of these disorders (see Section 1.4). The current study will further evaluate the effect of KH176 in various cognitive domains and evaluate the effect of different doses of KH176 (See Section 1.5). In view of the growing recognition of the importance of mitochondrial function in maintaining cognitive processes in the brain, as well as the understanding of the safety profile and pharmacokinetics of KH176 following the two clinical studies described above, a more detailed study is indicated of the effects of KH176 in various cognitive domains, using the confirmed safe and well-tolerated KH176 dose of 100 mg bid, as well as a lower dose of 50 mg bid. The primary objective is an evaluation of KH176 in the attention domain of cognitive functioning, as assessed by the visual identification test score of the Cogstate computerised cognitive testing battery.
Mitochondrial Diseases are rare, progressive, multi-system, often-early fatal disorders affecting both children and adults. KH176 is a novel chemical entity currently under development for the treatment of inherited mitochondrial diseases, including MELAS (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), MIDD (Maternally Inherited Diabetes and Deafness), Leigh's Disease and LHON (Leber's Hereditary Optic Neuropathy). The current Proof of Concept study aims to explore the effects of treatment with KH176 for 4 weeks on clinical signs and symptoms and biomarkers of mitochondrial disease and to evaluate the safety and pharmacokinetics of KH176 in patients with m.3242A\>G related mitochondrial disease.
Mitochondrial Diseases are rare progressive, multi-system, often early fatal disorders affecting both children and adults. KH176 is a novel chemical entity currently under development for the treatment of inherited mitochondrial diseases, including MELAS (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), Leigh's Disease and Leber's Hereditary Optic Neuropathy (LHON). KH176 is a potent intracellular redox modulating agent targeting the reactive oxygen species which are important in the pathogenesis of disorders of mitochondrial oxidative phosphorylation. After demonstrating a favourable safety profile in the pre-clinical testing, the safety, tolerability and pharmacokinetic and pharmacodynamic characteristics of the compound will now be evaluated in healthy male subjects in this trial
Khondrion begins study - On optimal dosage of new drug - Radboudumc go to main content Ga naar Mijn Radboud Emergency mijnRadboud About us Partners Working at On/Off contrast mode Readspeaker menu Listen Current language is Engels ( EN ) Pagina niet beschikbaar in Nederlands ( NL ) Seite nicht verfügbar auf Deutsch ( DE ) Go to Radboudumc Radboudumc Patient care Information Patient care International patients Healthcare costs Digital medical file Partners Vacancies close navigation Research I am interested in News Events Training and career Support and quality Ambition and impact Organiza … search groups Research programs Technology centers Departments Research support Grant support (intranet) Valorization (intranet) Academic development Bachelor's and master's students PhD candidates Postdocs Professors (& TTers + RGLs) Scientific Career Path Courses Why choose Radboudumc? close navigation Education Information for Students Bachelors and masters students PhD Candidates Postdocs Professors I want to know more about International Office Talent Managem … ational centers The phase 2b study is funded in part by a European Horizon 2020 grant of more than €2 million that the company received previously. The main outcomes of the study are the optimal dose of the drug and its efficacy for the patients participating in the study. These patients are being treated at three internationally recognized centers for mitochondrial diseases in Europe; the University of Newcastle (UK), LMU Munich (Germany) and Radboud university medical
%PDF-1.4 %���� 13809 0 obj > endobj xref 13809 44 0000000016 00000 n 0000004919 00000 n 0000005071 00000 n 0000005645 00000 n 0000006218 00000 n 0000006332 00000 n 0000006448 00000 n 0000006547 00000 n 0000007113 00000 n 0000007755 00000 n 0000010129 00000 n 0000012292 00000 n 0000012726 00000 n 0000013147 00000 n 0000013684 00000 n 0000013864 00000 n 0000013950 00000 n 0000014436 00000 n 0000015001 00000 n 0000017465 00000 n 0000019369 00000 n 0000021436 00000 n 0000021872 00000 n 0000023910 00000 n 0000026066 00000 n 0000028119 00000 n 0000033946 00000 n 0000037556 00000 n 0000040213 00000 n … ��n��;!�r� sP߬u#����{�zg�1��0j�%��`ue�* endstream endobj 13845 0 obj >stream application/postscript Adobe Illustrator CS2 2007-01-16T15:23:24-08:00 2007-01-16T15:23:24-08:00 2007-01-16T15:23:24-08:00 uuid:BE90B666A70711DB9541BA85B5488C0F uuid:BE90B667A70711DB9541BA85B5488C0F uuid:2F52977DA13211DABEA1CFC5EE2E89F6 uuid:2F52977CA13211DABEA1CFC5EE2E89F6 endstream endobj 13846 0 obj > endobj 13847 0 obj >stream application/postscript Adobe Illustrator CS2 2007-01-16T14:06:06-08 … 5948746f4 uuid:7dce71e0-f577-4f9c-bf19-d882d0e0d3a0 QuarkXPress(R) 9.54r1 False application/pdf Sheet endstream endobj 65 0 obj > endobj 66 0 obj >stream H��W�n�8} `��p�ndd��,i���[J���I�7J�$��Y��|�P���R]�����B ��� �s�X�;}�� �pc��i��:M�g.����4�l R�e���@��5̬ �%r ���(-(Ɋ��x�~J���B�qz��� �����=��F�fTU�������[Y�PӴE8������;.-? 0� )�����F=�n��:�f��8���3z�.����$& I���-ȿ*`�>W�e��D��~�s� �e�I�튐�I���q�]�$�K�jB�o���}N� )�u���� ���~��0�^c�8^�U����:ҋ���5 }����÷�[4�ȾY … c55ea62-e66d-46da-9270-92422fd2d7b0 uuid:1636af5c-781c-4b1e-83f7-a2b36a0d87c3 7 application/pdf Cassie Franklin Adobe PDF Library 11.0 D:20180531203916 Microsoft endstream endobj 248 0 obj > endobj 249 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/Properties >/XObject >>>/Rotate 0/StructParents 104/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>> endobj 250 0 obj >stream H��W[o�F~ׯ�G2(�3ù��@�Ď�I����C�(K��P,G���� II�w�ŦpEg��;�9sr�Z�m���ӓק/ϔm�Q���S5:y��^�go��|4��OF'�_�؍N&���\��6Ʃ�W … c55ea62-e66d-46da-9270-92422fd2d7b0 uuid:1636af5c-781c-4b1e-83f7-a2b36a0d87c3 7 application/pdf Cassie Franklin Adobe PDF Library 11.0 D:20180531203916 Microsoft endstream endobj 254 0 obj > endobj 255 0 obj >/Font >/ProcSet[/PDF/Text]>>/Rotate 0/StructParents 105/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>> endobj 256 0 obj >stream H����K�@ ���W�q}�
EISMEA Pharmaceutical Portfolio - 3 Companies | VCBacked Skip to main content VCbacked Search Digest YC Research Log in Get Started Home / Directory / Investors / EISMEA / Pharmaceutical Back to EISMEA EISMEA 's Pharmaceutical Portfolio Browse 3 Pharmaceutical companies funded by EISMEA . See funding amounts, founder contacts, and investment details. Pharmaceutical Companies 3 Total Funding in Pharmaceutical $11.8M Pharmaceutical Portfolio Companies ( 3 ) Export ChemiCare Health Care Pharmaceutical ChemiCare is committed to the discovery and development of orphan drugs for patients affect … clinical-stage pharmaceutical company. Nijmegen, The Netherlands May 2025 $5.7M Grant Founder Contacts [email protected] [email protected] 19,000+ verified contacts Get Instant Access Access Contact Information More EISMEA Portfolios by Industry Health Care 26 Biotechnology 25 Medical 15 Software 14 Manufacturing 13 Artificial Intelligence (AI) 12 Information Technology 10 Medical Device 9 Aerospace 9 Renewable Energy 6 Machine Learning 6 CleanTech 5 Explore EISMEA
About Khondrion - Radboudumc print page share page Close Listen About Khondrion Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds. Active discovery programmes are unde … search groups Research programs Technology centers Departments Research support Grant support (intranet) Valorization (intranet) Academic development Bachelor's and master's students PhD candidates Postdocs Professors (& TTers + RGLs) Scientific Career Path Courses Why choose Radboudumc? close navigation Education Information for Students Bachelors and masters students PhD Candidates Postdocs Professors I want to know more about International Office Talent Managem
%PDF-1.4 %���� 293 0 obj > endobj xref 293 44 0000000016 00000 n 0000001791 00000 n 0000001950 00000 n 0000004113 00000 n 0000004733 00000 n 0000005436 00000 n 0000005956 00000 n 0000006500 00000 n 0000006614 00000 n 0000007747 00000 n 0000008400 00000 n 0000008512 00000 n 0000009168 00000 n 0000009795 00000 n 0000010630 00000 n 0000011767 00000 n 0000012491 00000 n 0000013168 00000 n 0000014077 00000 n 0000014504 00000 n 0000015167 00000 n 0000015614 00000 n 0000015995 00000 n 0000017028 00000 n 0000017793 00000 n 0000018641 00000 n 0000019528 00000 n 0000019726 00000 n 0000020550 00000 n 000 … ��r8O�� ڰ4���zq������]g�cc���w �ޭ�;���=�N��f��g����8��@Y�.z�E� >stream application/postscript Utskrift Martin Olsson 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 xmp.did:e71fd692-22c4-2b49-a945-88e9ca718ed0 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:76c386df-ac92-6840-8abd-24ebb0c9bcfa xmp.did:76c386df-ac92-6840-8abd-24ebb0c9bcfa uuid:5D20892493 … ab6 2020-05-25T14:25:42+02:00 Adobe Illustrator 24.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:2e4c0b70-c8fa-b24f-bf98-d4b2a4884235 2020-05-25T14:45:22+02:00 Adobe Illustrator 24.1 (Windows) / saved xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) / Print False False 1 297.000000 210.000000 Millimeters Cyan Magenta Yellow Black Standardfärgrutegrupp 0 Vit CMYK PRO … bb564992b77 xmp.did:04756e0c-463e-4f97-a900-97da623b3a61 default converted from application/x-indesign to application/pdf Adobe InDesign 16.2 (Macintosh) / 2021-06-03T16:00:47+02:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 57 0 obj > endobj xref 0 293 0000000000 65535 f 0000728426 00000 n 0000730693 00000 n 0000736092 00000 n 0000784466 00000 n 0000784709 00000 n 0000785162 00000 n 0000981217 00000 n 0000982219 00000 n 0000994218 00000 n 0000996495 00000
%PDF-1.7 %���� 1 0 obj >/Metadata 896 0 R/ViewerPreferences 897 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 22 0 R 25 0 R 26 0 R 29 0 R 30 0 R 31 0 R 32 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=�r�H��#tYyӥ��c]U����ڭm��>T�2V4 F{ �z߮�櫿]}}Z�W_Ƴl9^g���v�}��~I�Ӵ��'�݇����\~����y��� �Œ� ��������-�\������#�����[�y�K_y1 �����[~���Y ����]\����ŷ�7�����77�e��������I��%��/�/ >���} �� [� ���e8��P��H V�0 d� K��.�#ȉ�klp�x�$���4�'��� Z���ï� �|0�
Mitochondrial Myopathies Market to Register Stunning Growth at a CAGR of 26.5% During the Forecast Period (2025-2034) Driven by Recent Approvals and Pipeline Advancements and Rising Awareness | DelveInsight Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
424B4 1 d63585d424b4.htm 424B4 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-254534 PROSPECTUS 6,250,000 Shares Common Stock We are offering 6,250,000 shares of common stock. This is our initial public offering. Prior to this offering, there has been no public market for our common stock. The initial public offering price is $15.00 per share. Our common stock has been approved for listing on the Nasdaq Global Market under the symbol “RPHM.” We are an “emerging growth company” under applicable Securities and Exchange Commi … ve dates for public and private companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with n … ds from this offering, together with our existing cash and cash equivalents, to fund the research and development of REN001, for commercial readiness preparations, for other research and development activities, and for working capital and general corporate purposes. See the section titled “Use of Proceeds” for additional information. Risk factors See the section titled “Risk Factors” and other information included in this prospectus for a discussion … ds, together with our existing cash and cash equivalents, will be sufficient to fund our operations for at least the next 24 months. However, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. Our future capital requirements will depend on many factors, including: ∎ the scope, progress, … n initiate clinical trials for REN001 or any future product candidates, we must submit the results of preclinical studies to the FDA or comparable foreign regulatory authorities, along with other information, including information about chemistry, manufacturing and controls, and our proposed clinical trial protocol, as part of an IND or similar r
Pierrepont Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Pierrepont Therapeutics, Inc. Holding Company | 2020 | Pennsylvania, United States | 10-50 | www.pierreponttx.com Holding Company | 2020 | Pennsylvania, United States | 10-50 | www.pierreponttx.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Pierrepont Therapeutics, Inc. Login to view more data 0 Pate … , Inc. 21 Nov 2024 · www.globenewswire.com UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease 21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondria … e and muscle weakness. With the support and investment by the UMDF via The Mito Fund, we look forward to further progressing our clinical work on sonlicromanol at pace in our upcoming Phase III trial in adult patients with PMD.” Like all investments made by The Mito Fund, the Khondrion consideration went through a rigorous review process by UMDF’s Venture Philanthropy Investment Committee, an advisory group consisting of world-class experts in the areas of mitochondrial disea … rapeutic in a patient-centric manner.” Launched in the summer of 2023, The Mito Fund is UMDF’s most ambitious effort to date to ramp up the development of mitochondrial disease treatments and cures. The fund’s venture philanthropy model is designed not only to financially support the development of the next generation of mitochondrial disease treatments, but also to leverage UMDF’s experience and network to accelerate the development process and lower the risk associated with … investors and researchers. This is the second official investment for The Mito Fund. In April 2024, the fund announced an investment in Pierrepont Therapeutics, Inc., which is working on a preclinical proprietary intracellular enzyme replacement therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). Companies exploring the mi
We’re proud to provide continous support to Khondrion Skip to content Get in touch with one of our Xperts. Our Solutions Chemistry, Manufacturing, & Control (CMC) Non-Clinical Clinical Regulatory Affairs Leadership Project Management About Us About 3D-PharmXchange Managing Partners News & Insights Blog News Careers Contact Us We’re proud to provide continous support to Khondrion as an important milestone is reached in the Phase 3 KHENERFIN study with the treatment of the first patient The first patient has been dosed in the pivotal Phase 3 KHENERFIN study evaluating sonlicromanol for
Pierrepont Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors &a … rrepont Therapeutics News Pretzel Therapeutics: Investment Raised From The Mito Fund Jul 14, 2025 The United Mitochondrial Disease Foundation’s venture philanthropy arm, The Mito Fund, has invested in Pretzel Therapeutics, a Massachusetts-based company with research facilities in Mölndal, Sweden. Pretzel is focused on using cellular energetics to improve survival and quality of life for various conditions. The lead program, PX578, recently entered Phase 1 clinical development … ients. Currently, there is no FDA-approved therapy for these diseases. The Mito Fund conducts a thorough review process for investments, overseen by a committee of experts in mitochondrial disease and pharmaceutical development, and approved by UMDF’s Board of Trustees. Launched in summer 2023, the Mito Fund seeks to advance the development of treatments for mitochondrial diseases, providing financial support while leveraging UMDF’s expertise to minimize risks for investors a … se to minimize risks for investors and researchers. Other companies in the Mito Fund portfolio include: — Napigen Therapeutics – A company that aims to harness the potential of mitochondria to impact human healthcare with its unique organelle genome editing tools. — Pierrepont Therapeutics – A company focused on advancing to the clinic a proprietary intracellular enzyme replacement therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). — Khondrion – A clin … ficer Dr. Philip Yeske “We are honored to receive this investment from The Mito Fund, whose commitment to improving the lives of patients living with mitochondrial disease aligns deeply with our mission. This funding not only validates the promise of our scientific approach, but also supports development of PX578, the lead therapeutic in our ener
G primary mitochondrial disease. This milestone marks an important step as the program advances into the registrational phase of development. The randomized, placebo-controlled Phase 3 trial is being conducted across sites in Europe, the UK, and the US, addressing a rare condition with significant unmet medical need and no approved disease‑modifying treatments. 3D-PharmXchange is proud to support KHONDRION as a strategic partner in this Phase 3 journey, contributing CMC and QA expertise to help ensure the program’s readiness for this pivotal stage. Our congratulations go to the KHONDRION team … United States. In Europe, we have already submitted our marketing authorization application. Why this matters: more people suffer from chronic pain than from cardiovascular disease, cancer and diabetes combined. And yet, therapeutic progress in this field has lagged behind the need for decades. For many patients, opioids remain the only option – with severe side effects and a high potential for addiction. The data behind this decision: – In our Phase 3 study, VER-01 delivered
Asceneuron today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors. - Asceneuron About us Mission & History Investors Research & Development Pipeline Publications News & Events Contact Contact us Select Page Press releases Asceneuron today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors. Asceneuron SA, an emerging leader in the development of innovative small molecules targeting tauopathies such as progressive supranuclear palsy (PSP), Alzheimer’s disease and related neurode
%PDF-1.7 %���� 1 0 obj >/Metadata 361 0 R/ViewerPreferences 362 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 12 0 R 13 0 R 14 0 R] /MediaBox[ 0 0 594.96 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][s�8�~OU� �-�!$w]�� g.��dc����>02eq"K ��'�ן�$%�N �����"�����u�zuR7ռ�5��ѫ��)f��*��������.�ܖ���ժh���������/���>>N_���������?_��:�$H�$�T��GY�����#XA�Pĉ�0�i�� ����(��vO���/^�+�" ^����E���,�:��$Wa��L�xc���K��������ZGЗ��� ���� %�s"Jf�^Hm��e]�_*-��w2�P�L�K&|�d��p˥��y���c�����P … 93>> startxref 262639 %%EOF 361 0 obj >stream Microsoft® Word for Microsoft 365 application/pdf Microsoft® Word for Microsoft 365 2024-12-20T13:18:56+01:00 2024-12-20T13:22:06+01:00 2024-12-20T13:22:06+01:00 uuid:9EB069B8-AA8C-4BB9-BFF8-A9E14C5B0D78 uuid:0e45ab91-4e49-424e-af1a-9236a0d2c624 endstream endobj 364 0 obj > endobj xref 0 1 0000000000 65535 f 361 1 0000262823 00000 n 364 1 0000266308 00000 n trailer ]/Prev 262639>> startxref 266498 %%EOF
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Khondrion | KH176 Phase 2 clinical trial About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact KH176 Phase 2 clinical trial Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes NIJMEGEN, The Netherlands – Khondrion, the clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the initiation of the KHENERGY study, a Phase 2 clinical trial with KH176 in patients harboring the m.3243A>G mutation i
We have started a quality assurance project with Sjællands Universitetshospital (CHIP-klinikken) evaluating the CO rebreathing method as a more precise way to support diagnosis and treatment… | Detalo Health LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any tim … a comment, sign in INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center 18,334 followers 1mo Report this post We are pleased to announce our strategic partnership with Immunosis to bring advanced RNA-based diagnostic technology for immune dysregulation to the MENA region. Click the link to read the full announcement. https://lnkd.in/d9Qj7sJs 59 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Oskar Bednarczyk 2
News | Lifesciences @ Work Skip to main content Lifesciences @ Work Main navigation Programs Venture Challenge Expert Classes Value Centre Mentor Matching Startups News Events About us Advisory board Meet the team Our partners News Prolira signs collaboration with Orion Pharma for sales of DeltaScan in Germany 20 June 2021 The companies ORION Pharma and Prolira are excited to announce their sales collaboration agreement that has been signed in June 2021. Venture Challenge Summer 2021: Meet the Teams! 7 June 2021 Last week, the Venture Challenge Summer 2021 kicked off with innovative Life Scien … g science foundation. Venture Challenge alumnus Scope wins AtlasInvest Start-Up Award 28 May 2021 Scope Biosciences was announced as one of the two winners of the AtlasInvest Entrepreneurship Grant during the F&A Next Want to further develop your business skills? Then register for the TAP BioBusiness training programme 12 May 2021 Are you a future BioBusiness leader in Life Sciences & Health? Register now for the TAP BioBusiness training programme and benefit from the
Mitochondrial Disease Therapies Market Report, Industry Size & Revenue, Share, Forecast 2024–2030 [email protected] 92, An Guha Lane, Arya Samaj Gali, Sambalpur, Odisha -768001 IN: +91-826-083-6500 Home About Why SMR Research Methodology Media Coverage Join Our Team Reports Aerospace and Defense Agriculture Automotive Chemicals and Materials Consumer Goods Energy and Power Equipment and Machinery Food and Beverages Healthcare Information and Communication Technology Semiconductor and Electronics Manufacturing and Construction Our Practices Syndicated Research Consulting Se … d mitochondrial dysfunctions. Its strategy is to develop molecules with broader application across metabolic and neuromuscular diseases, giving it both rare disease and mainstream potential. Astellas Pharma Astellas Pharma has entered the space through partnerships and acquisitions, betting on gene therapy as a long-term play. The company’s investment in mitochondrial replacement therapy research highlights how major pharmaceutical players are selectively backing … groups often help deliver access indirectly. They coordinate trial enrollment, fund diagnostic programs, and in some cases, subsidize early access schemes. Their involvement is unique in shaping end-user dynamics. Use Case Highlight: A leading children’s hospital in London faced challenges managing pediatric patients with mitochondrial myopathy. Treatment options were limited to supportive care, often leaving families frustrated. The hospital partnered with a bi
Advanced Therapies and OXGENE acquired by Altaris | Advanced Therapies, LLC posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
See you next week @EUROMIT 2026?! | Jasper Levink LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , an
Khondrion - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Cor … lands Stage Seed Latest Funding Round Seed, Nov 21, 2024 , $***** Investors EIC Fund & 2 more Ranked 119 th among 260 active competitors Similar Companies Alnylam & 294 more View Khondrion's full profile Sign up to download Khondrion's company profile Sign Up for Free Khondrion's funding and investors Khondrion has raised funding over 6 round s . Its first funding round was on Dec 01, 2015 . Its latest funding round was a Seed round on Nov 21, 2024 for … Nov 21, 2024 5389363 Seed 1164607 6970004 5912351 8937338 Nov 01, 2022 1781018 Grant (prize money) 3239884 9780361 2496846 Europa Sep 30, 2021 3113846 Grant (prize money) 1013372 2103343 8180008 EIC Fund Access funding benchmarks and valuations. Sign up today! View details of Khondrion 's funding rounds and investors Khondrion's founders and board of directors Founder? Claim Profile The founders of Khondrion is Jan Smeitink . Jan Smeitink is the CEO of Khondrion . … therlands ) , Seed Small molecule therapeutics for mitochondrial diseases - EIC Fund , Europa & 1 others 41/100 Get insights and benchmarks for competitors of 2M+ companies! Sign up today! Looking for more details on Khondrion 's competitors? Click here to see the top ones Khondrion's Investments and acquisitions Khondrion has made no investments or acquisitions yet. News related to Khondrion Filter this list Media has covered Khondrion for a total of 2 events i … . PR Newswire • May 06, 2025 • Khondrion • UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease GlobeNewswire • Nov 21, 2024 • Khondrion , Umdf • Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … ation Credit from the Dutch government, complemented by private investments, to fund the first wave of its Phase 3 trial for sonlicromanol in m.3243A>G Primary Mitochondrial Disease. Sonlicromanol, a first-in-class small molecule therapy, has shown progressive symptom improvements in Phase 2 trials and maintained a favorable safety profile in patients receiving the drug for over two and a half years. The pivotal Phase 3 trial is scheduled to launch in the second half of 20
Khondrion announces publication in Brain of integrated Phase 2b program demonstrating disease-modifying potential of sonlicromanol in primary mitochondrial disease Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Prem … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS
The Mito Fund Announces Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease - UMDF Mitochondrial Disease Resources Medications Insurance Assistance Forzinity Kygevvi Get Involved Research About Us About Us 2026-2029 Strategic Plan 2025 Annual Report Donate Donate Now Energy for Life Family Tribute Pages Match Your Gift Get Support The Mito Fund Announces Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease Press Room , Research News The United Mitocho … ed Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease (PMD). Khondrion is currently preparing to initiate a Phase III study investigating the potential of its lead proprietary drug candidate, sonlicromanol, to treat adult patients with PMD due to the m.3243A>G mutation, the most … e and muscle weakness. With the support and investment by the UMDF via The Mito Fund, we look forward to further progressing our clinical work on sonlicromanol at pace in our upcoming Phase III trial in adult patients with PMD.” Like all investments made by The Mito Fund, the Khondrion consideration went through a rigorous review process by UMDF’s Venture Philanthropy Investment Committee, an advisory group consisting of world-class experts in the areas of mitochondrial disea … rapeutic in a patient-centric manner.” Launched in the summer of 2023, The Mito Fund is UMDF’s most ambitious effort to date to ramp up the development of mitochondrial disease treatments and cures. The fund’s venture philanthropy model is designed not only to financially support the development of the next generation of mitochondrial disease treatments, but also to leverage UMDF’s experience and network to accelerate the development process and lower the risk associated with … investors and researchers. This is the second official investment for The Mito Fund. In April 2024, the fund announced an investment in Pierrepont Therapeutics, Inc., which is working on a preclinical proprietary intracellular enzyme replacement therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). Companies exploring the mi
Tom McWilliams wins Wellcome Trust poster prize | MRC PPU Medical Research Council Protein Phosphorylation and Ubiquitylation Unit Search Submit Use Advanced Search Facility Protein transformations that change lives How our research can help yours… Sequencing Reagents DUB Kinase Covid --> Skip to main content --> Home About Us About the MRC PPU Phosphorylation and Ubiquitylation List of Clinically Approved Kinase Inhibitors Our Values Integrity Collaboration Public and Patient Involvement and Engagement Equity, Diversity and Inclusion Environmentally Sustainable Research Our Research Overview … minars and Lectures News Join Us Life In Dundee Study With Us Our PhD Programme Apply Now For Current Projects Parkinson's Disease and Neurodegeneration PhD Programme Cancer and Genome Integrity PhD Programme Chemical Biology and Structural Biology PhD Programme Tricia Cohen Prize Studentship Visiting Clinical Scholar Awards Work With Us Contact Tom McWilliams wins Wellcome Trust poster prize Tom McWilliams wins Wellcome Trust poster prize Thu 12th May 2016 Tom McWilliam … liams, a postdoctoral researcher with the Ganley and Muqit labs, won the poster prize for Best Basic Science Poster (sponsored by Khondrion ) at the recent Wellcome Trust Conference on 'Mitochondrial Medicine: developing new treatments for mitochondrial disease'. The 3-day meeting was held at the Wellcome Genome Campus at Hinxton in Cambridge, and showcased a broad spectrum of research in the field of mitochondrial biology. Tom presented exciting data on his characterisation … nging from cancer to neurodegeneration. Recently, Tom was also awarded a travel grant from The Guarantors of Brain , who provide funding for clinical and academic neuroscientists to attend conferences and present original research. Tom will use this to attend the prestigious 2016 Gordon Research Conference on Lysosomes and Endocytosis in the United States next month, and give a talk at the Gordon Research Seminar on his recent work on mitophagy. Congratulations Tom for this a
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
%PDF-1.6 %���� 31018 0 obj > endobj 31042 0 obj >/Filter/FlateDecode/ID[ ]/Index[31018 41]/Info 31017 0 R/Length 116/Prev 1964609/Root 31019 0 R/Size 31059/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"n�H� ��D2+�E���) �e=X�D�ƃ� `� ,� �6� >stream h�b```�O � l� � cc`a�X�$���q@�E�� H0��5 �x(���A͇R�� RD&0��R} �Qf�� � ��D�X�Y�9� ���4#k�t�ն�f��~��M4 $�����2�)�L82������)��m�M�� ��.h\V�Pb�t8(���C��3����8-k���"�F�`$�s� �G̀5�/ԟ ?�~��B]F��n �y���M���Dϐ�ʭ��Ҵ�1���C|��6�u\�[���]άp*Q+��y�ŝI_1�@Ϗ� M�� Z> *j4jXb�ݣ�Cd"�:K5S�� â�� y+c�V�s� 5\h�p١�"�ɩ��T��-��"�A_@x��+L … �V��L����QH@+������S�-��t]�,^������� q� �V;�e���Х��Bzqp춀B1ӫm1�5�`� ��Wz '�RFP����MA�(�鬌!�c��_�cKR bϝ�K8�V| MGS�IWp��RV�~|)f�\� �Z9)���Ҧ�u����/�5�!ޅ��(&I�7)��qD�ni�BBZ�]��Tx)�6��aS3� D��A���z�}�6��0�(3�� )��e��S��7�֙b� 3�t�Z��4��'8y��� �:A\nΣ#lp�E���#��� k����k�T����Y��^�������Q��Y���D���*5������-> ��^#V�\qg��n�{�(�{7=*:����QW� Ùęs�����FϺ�c+��)m�Z�^�B3��C� �-c| MUs��M�u!i,~*d�(b�v6��FЍC�em4Cz��1��!oi�{_]\` �n �O����f�q�5���wt � fVr�� … 44f2944-be26-48ba-a55a-a44a0190ce7f uuid:0a5c5de9-8cba-451f-99f1-9df4b5b421cd 2 application/pdf Annexes – 2024 annual report of the European Medicines Agency European Medicines Agency (EMA) Adobe PDF Library 26.1.183 Annual report 2023 D:20260518133105 European Medicines Agency Template developed for European Medicines Agency by Fiona Lewis and Vanessa Crookes December 2009 Internal All EMA Staff and Contractors Annual report emea_document 1.1,CURRENT d4f06ab887b11752bc4a51b0 … 44f2944-be26-48ba-a55a-a44a0190ce7f uuid:dc7de2d9-7b0f-49c4-b739-79aeff276bb6 2 application/pdf Annexes – 2025 annual report of the European Medicines Agency European Medicines Agency (EMA) Annual report 2023 Adobe PDF Library 26.1.183 Annual report 2023 D:20260518133105 European Medicines Agency Template developed for European Medicines Agency by Fiona Lewis and Vanessa Crookes December 2009 Internal All EMA Staff and Contractors Annual report emea_document 1.1,CURRENT d4f06
BioCentury - Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more This Edition ARTICLE | Company News Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more Hongjiang Li and Elizabeth S. Eaton, Staff Writers December 11, 2019 1:55 AM UTC Updated on Dec 11, 2019 at 7:06 PM UTC ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth
Khondrion | Khondrion welcomes Hans Schikan About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion welcomes Hans Schikan Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that Hans Schikan, former CEO of Prosensa, has joined Khondrion’s Advisory Board. “We are delighted that Hans Schikan has joined our Advisory Board”, said Jos Lamers, chairm
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��=is �r��+��.w�� ��%�4W�H� ���%��Jů�����4���8~U�\e��F��h����I]�I���������=����n ���h#��7
Stichting Energy4All | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors Stichting Energy4All Stichting Energy4All Zeeland energy4all.nl Overview Stichting Energy4All is a Dutch non-profit foundation that raises funds to support and accelerate research for a treatment for mitochondrial diseases, primarily supporting the work of the company Khondrion. Year Founded 2006 Portfolio Companies 1 Website energy4all.nl Investments Company Date Stage Lead Khondrion May 2025 VC Rou
Khondrion appoints Jasper Levink as Chief Financial and Business Officer Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tennis NFL Athletics Cycling NBA Motorspor … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,103.00 +55.40 +1.37% ADVERTIS
Help us welcome,... - United Mitochondrial Disease Foundation Facebook Log In United Mitochondrial Disease Foundation's Post United Mitochondrial Disease Foundation May 26, 2025 · Shared with Public Help us welcome, ABLIVA - a member of Pharming Group, silver sponsor for this year's Mitochondrial Medicine Conference! Thank you for prioritizing the #mito patient community and helping us build the best #MitoMed Conference in St. Louis. Learn more about our generous sponsors at umdfconference.org/2025-sponsors All reactions: 3 1 share Like Comment
Khondrion | Khondrion and Amsterdam UMC announce to initiate Phase 2 Clinical Trial of Sonlicromanol to Combat Long-Term Post-COVID Symptoms About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion and Amsterdam UMC announce to initiate Phase 2 Clinical Trial of Sonlicromanol to Combat Long-Term Post-COVID Symptoms NIJMEGEN, The Netherlands – November 8, 2024: Khondrion, a clinical-stage biopharmaceutical company specializing in mitochondrial disease therapies, and Amsterdam UMC together with Vrije University Amsterdam ha … MC valuable early insights into the drug’s potential effectiveness for this new application. Prof. Dr. Jan Smeitink, CEO of Khondrion, highlighted the versatility of the drug: “Sonlicromanol, which has advanced to Phase 3 development for primary mitochondrial diseases, shows promise as a ‘pipeline-in-a-product’ due to its unique triple mode of action that combats the pathomechanisms that are common to many forms of mitochondrial dysfunction. We’re excited to explore how sonli
%PDF-1.7 %���� 6103 0 obj > endobj 6113 0 obj >/Filter/FlateDecode/ID[ ]/Index[6103 23]/Info 6102 0 R/Length 72/Prev 7838493/Root 6104 0 R/Size 6126/Type/XRef/W[1 3 1]>>stream h�bbd```b`�8"U@$S�dn��= R�2X�:�d�X "��俩@YF�4�,P7���W|� m endstream endobj startxref 0 %%EOF 6125 0 obj >stream h��V�o��;��p���\���R'i���4iⶬ���M�Q ��Lf���hIK�M�9��K����(-�u+(*(E� ����PT���TuY�� ֲ � �� m{wNa?������}�}ޏ��~u_@���`D��Qgp�. ��RD"�mp"-�r?h������I�p����� ل� ¶!a�&*G�Ճ�-��#�~ Ke�ȝO��X��ʇ�J���� �\� �{� w�m�������M}O� E�_�n� ԇ��+�Z�>{���}*L�LĕMu%nx����������@c���Ձ������6HIy��� … t*� endstream endobj 803 0 obj >stream Microsoft® PowerPoint® for Microsoft 365 application/pdf Adam Schreiber Microsoft® PowerPoint® for Microsoft 365 2026-02-11T14:39:10Z 2026-02-11T14:43:30Z 2026-02-11T14:43:30Z uuid:B2BDE2A7-D7C6-43E6-8C16-85189FAFA143 uuid:d84d69a9-866d-49cb-91cb-9e9a6dea8482 endstream endobj 804 0 obj >stream h� >stream h�2340R0P���w,-��/�pLI�UN�(J�LJ-��w.JM,���sI,I�p�22023024441�44�����f&�秕�S�/O- �������R �f�����)��� (�O)MN%Ŵ�̒�T M;;���A� en … ̛7P���_�k��ym�̌o!�*I���倏2�r >stream Microsoft® PowerPoint® for Microsoft 365 application/pdf Microsoft® PowerPoint® for Microsoft 365 2026-02-11T14:39:10Z 2026-03-05T17:25:20+01:00 2026-03-05T17:25:20+01:00 uuid:B2BDE2A7-D7C6-43E6-8C16-85189FAFA143 uuid:ddad9e50-efb3-434c-8434-994efb8407fb endstream endobj 6126 0 obj > endobj 6127 0 obj >/Filter/FlateDecode/ID[ ]/Index[803 1 6126 2]/Info 6126 0 R/Length 24/Prev 116/Root 6104 0 R/Size 6128/Type/XRef/W[1 3 0]>>stream h�bb,_j
Khondrion | Khondrion announces publication in PLOS ONE of new research showing normalisation of prostate cancer stem cell mPGES-1 overexpression and inhibition of cancer spheroid growth by sonlicromanol’s active metabolite About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion announces publication in PLOS ONE of new research showing normalisation of prostate cancer stem cell mPGES-1 overexpression and inhibition of cancer spheroid growth by sonlicromanol’s active metabolite Khondrion, a clinical-stage biopharmaceutica
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
🌲 Khondrion’s 2024 Achievements and Festive Outlook for 2025 As the year draws to a close, Khondrion celebrates a transformative 2024—a year marked by milestones that bring us closer to delivering… | KHONDRION LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any … ment this November, the FDA approved Khondrion’s Investigational New Drug (IND) application for sonlicromanol, enabling a Phase 3 trial in the U.S. This approval represents a key step in bringing this innovative therapy to market. Scientific Recognition – Phase 2b Results Published Data published in Brain highlights the groundbreaking potential of sonlicromanol to alleviate chronic fatigue and muscle weakness—two of the most burdensome symptoms of PMD. This recognition reinfo … l value of our lead candidate. Strategic Investment – Partnership with The Mito Fund Support from The Mito Fund underscores confidence in sonlicromanol and provides additional resources to advance its development. Together, we’re forging a brighter future for patients. 🔜 Looking Ahead to 2025: A Year of Opportunity As we ring in the new year, Khondrion is poised to continue its journey of innovation and impact. Key priorities include: Phase 3 Trial Launch: In 2025, we will i
%PDF-1.5 %���� 268 0 obj > endobj xref 268 27 0000000016 00000 n 0000002208 00000 n 0000002322 00000 n 0000003409 00000 n 0000003951 00000 n 0000004704 00000 n 0000004741 00000 n 0000004855 00000 n 0000005132 00000 n 0000005718 00000 n 0000006000 00000 n 0000006603 00000 n 0000007397 00000 n 0000008126 00000 n 0000008804 00000 n 0000009524 00000 n 0000010181 00000 n 0000010887 00000 n 0000011643 00000 n 0000012225 00000 n 0000014875 00000 n 0000028509 00000 n 0000042102 00000 n 0000043822 00000 n 0000043861 00000 n 0000044761 00000 n 0000000836 00000 n trailer ]/Prev 1134959>> startxref 0 %%EO … �A�ѱq��[�BJ��H�0�/M���T.-z�%MΝ�-�����-��]�$ endstream endobj 290 0 obj >stream application/postscript CRP Administrator umdf_wht_mbrand_r_lg.eps Adobe Illustrator CS2 2007-01-16T12:23:38-08:00 2007-01-16T12:23:38-08:00 2007-01-16T12:23:38-08:00 uuid:B1E17A12A6ED11DB9541BA85B5488C0F uuid:B9AA0178A6EE11DB9541BA85B5488C0F uuid:2F52977FA13211DABEA1CFC5EE2E89F6 uuid:2F52977EA13211DABEA1CFC5EE2E89F6 endstream endobj 291 0 obj > endobj 292 0 obj >stream 1 2 3 0 endstream endobj 293 … 1916.000000 1342.000000 Pixels Cyan Magenta Yellow Black Default Swatch Group 0 application/pdf Picture4 xmp.did:24b60714-a1e2-fb4c-93f3-854bbd2a30dc uuid:e9a038fa-0b35-4e45-875d-3a329b7d5da7 xmp.did:a3f9dba0-99aa-fe48-bb7b-af6723e2d2f9 proof:pdf xmp.iid:a3f9dba0-99aa-fe48-bb7b-af6723e2d2f9 xmp.did:a3f9dba0-99aa-fe48-bb7b-af6723e2d2f9 xmp.did:a3f9dba0-99aa-fe48-bb7b-af6723e2d2f9 saved xmp.iid:a3f9dba0-99aa-fe48-bb7b-af6723e2d2f9 2026-01-23T09:39:00-05:00 Adobe Illustrator 30. … Pixels Cyan Magenta Yellow Black Default Swatch Group 0 Document False AIRobin application/pdf Picture5 proof:pdf uuid:6dfc4287-2fc2-4d56-9f22-c3e576e4e0f5 uuid:ff8ff1eb-128b-4241-8185-f059695d03c2 Adobe PDF library 17.00 endstream endobj 124 0 obj > endobj 125 0 obj >stream H�\��j�0 ��~ �CI���i 9�e{��V���'=��'E������d�QU k��2z�i`�]�l�i���މ]"mo��n����"��f�fj�(d�� ��l� lD�,��]��W�ld�ܼ���,cY��B�B/�m����-���Ř?��ŃL����1��ɷB� �W)�3�R���Γ��.��n�(r�c4�H�ӕ�8gΑ … ��؍*ٙpW��p z9��h0ɟ�h ��n�?� +�����0��t%$Q��� .��� �B�ܘI��.�L�����9� >stream application/postscript CRP Administrator umdf_wht_mbrand_r_lg.eps Adobe Illustrator CS2 2007-01-16T12:23:38-08:00 2007-01-16T12:23:38-08:00 2007-01-16T12:23:38-08:00 uuid:B1E17A12A6ED11DB9541BA85B5488C0F uuid:B9AA0178A6EE11DB9541BA85B5488C0F uuid:2F52977FA13211DABEA1C
Khondrion | Khondrion announces publication in Scientific Reports outlining an additional anti-inflammatory mode of action for its lead phase IIb-stage drug candidate sonlicromanol About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion announces publication in Scientific Reports outlining an additional anti-inflammatory mode of action for its lead phase IIb-stage drug candidate sonlicromanol Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
#mitochondrialdisease #raredisease #clinicaltrials #phase3 #biotech | KHONDRION LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A
Khondrion | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Khondrion Website: Khondrion Business Area(s) Mitochondria Therapeutics Description Develops targeted and highly innovative solutions for people suffering from mitochondrial diseases. Company Location(s) Philips van Leydenlaan 15 6525 EX Nijmegen Netherlands body Sign up for news Contact Us Add
Khondrion | News About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact stay updated Explore the latest news from Khondrion and its team. Khondrion press releases October 9, 2024 Khondrion to present at Mitocon’s 14th Mitochondrial Disease Conference NIJMEGEN, the Netherlands – 9 October, 2024: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting... Read more September 11, 2024 Khondrion appoints Jasper Levink as Chief Financial and Business Officer NIJMEGEN, the Netherlands – 11 Se … eveloping therapies targeting... Read more November 1, 2023 Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1 Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1... Read more March 23, 2023 Khondrion joins the NADIS International Student Training Network Khondrion has joined a recently estab
Khondrion | Khondrion awarded H2020 SME Instrument grant About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion awarded H2020 SME Instrument grant Khondrion receives €2.3M funding from EU Horizon 2020 SME instrument phase 2 program NIJMEGEN, the Netherlands – The Netherlands – Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases was awarded €2.3M from the highly competitive EU Horizon 2020 SME instrument program (grant agreement nr 830115). The gra … 1664 proposals. Jan Smeitink, Khondrion’s CEO, said “This H2020 SME instrument grant is a great opportunity for Khondrion enabling us to accelerate the clinical development of KH176 for patients suffering from mitochondrial disease who have an unmet medical need for clinical relevant treatments. We are extremely proud to be awarded with the most competitive grant for SME’s in Europe and are eager to start and bring this innovative project to a success.” About KH176 KH176 is
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Jobs and Career Opportunities in Europe | EURAXESS Skip to main content Log in Search Search EURAXESS Researchers in motion Menu Close Menu Back Home Jobs & Opportunities Find Jobs & Opportunities Living & Working in Europe Coming to Europe Living in Europe Working in Europe Retiring in Europe Country information search Leaving Europe Career Development For Researchers For Organisations Initiatives Science4Refugees ERA4Ukraine Network EURAXESS National Portals EURAXESS Network Map EURAXESS Worldwide EURAXESS Support Centres ERA Talent Platform HR Excellence in Research RESAVER Rese … offer JOB Netherlands Khondrion Posted on: 15 November 2022 Marie Curie (MSCA) fellowship in NADIS project: Improving NAD+ homeostasis in metabolic disease and novel therapies Apply now Page contents Job Information Offer Description Where to apply Requirements Additional Information Work Location(s) Contact 15 Nov 2022 Job Information Organisation/Company Khondrion Research Field Biological sciences Medical sciences Researcher Profile First Stage Researcher (R1) Application … ces Medical sciences Researcher Profile First Stage Researcher (R1) Application Deadline 15 Dec 2022 - 22:00 (UTC) Country Netherlands Type of Contract Temporary Job Status Full-time Hours Per Week 40 Is the job funded through the EU Research Framework Programme? H2020 / Marie Skłodowska-Curie Actions Marie Curie Grant Agreement Number 101073251 Is the Job related to staff position within a Research Infrastructure? No Offer Description We have a vacancy for a doctoral candida … metabolic research and, specifically, NAD+ research in Europe. Where to apply E-mail [email protected] Requirements Research Field Biological sciences Education Level Bachelor Degree or equivalent Skills/Qualifications We seek a highly motivated scientist who has an affinity with cell culture and biochemistry/cell biology is intellectually independent but practically a team player for our small research team. The research project should result in a PhD thesis. To … (MSCA)of the European Union's Europe 2022 research and innovation program under grant agreement No 101073251. You will be appointed as fulltime PhD for 3 years at Khondrion B.V and enlisted into the RIMLS graduate school. The NADIS project is committed to a policy that supports diversity and inclusion, and thus the selection process will have thi
G primary mitochondrial disease. This milestone marks the transition into the registrational stage of development for a progressive, multi-system disease with significant unmet medical need and no disease-modifying treatment options today. The KHENERFIN study is designed to assess outcomes that matter most in daily life—fatigue and physical function—building on consistent signals observed in our Phase 2 program. As the study progresses, focus will be on execution, data quality, and patient engagement to generate the evidence required to support potential registration. We thank the patients, in
Khondrion | New Patents granted for KH176 About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact New Patents granted for KH176 New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the grant of key patents in the United States of America (US 9,388,156 B2), Europe (EP 2872497) and Hong Kong (HK 15110180.2) providing protection for its library of c … ad clinical-stage KH176 for the treatment of mitochondrial related disease. The grant of these patents provides the company exclusive rights for KH176 and the other compounds of the library until at least July 2033. “We are extremely satisfied with the granting of this important asset within our IP portfolio”, said Jan Smeitink, CEO of Khondrion. “The grant of these patents brings further recognition of the quality of the innovation being carried out by the Khondrion team. We
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
KHONDRION | Jasper Levink LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip t … pioneers to transform ex vivo CGT into in vivo. Our name Tiva (Targeted in vivo application) reflects our expertise in creating sophisticated, targeted LNPs (tLNPs) that deliver molecules precisely where it needs to go. We enable our clients at every stage of their development pipeline with: • Comprehensive tLNP services, from 10 µg screening to gram-scale process development and manufacturing. • Specialized analytical testing, including conjugation efficiency and surface lig
Khondrion | UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease 21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in K … e and muscle weakness. With the support and investment by the UMDF via The Mito Fund, we look forward to further progressing our clinical work on sonlicromanol at pace in our upcoming Phase III trial in adult patients with PMD.” Like all investments made by The Mito Fund, the Khondrion consideration went through a rigorous review process by UMDF’s Venture Philanthropy Investment Committee, an advisory group consisting of world-class experts in the areas of mitochondrial disea … rapeutic in a patient-centric manner.” Launched in the summer of 2023, The Mito Fund is UMDF’s most ambitious effort to date to ramp up the development of mitochondrial disease treatments and cures. The fund’s venture philanthropy model is designed not only to financially support the development of the next generation of mitochondrial disease treatments, but also to leverage UMDF’s experience and network to accelerate the development process and lower the risk associated with … investors and researchers. This is the second official investment for The Mito Fund. In April 2024, the fund announced an investment in Pierrepont Therapeutics, Inc., which is working on a preclinical proprietary intracellular enzyme replacement therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). Companies exploring the mitochondrial science space are encouraged to start a conversation about investment opportunities at www.themitofund.org . Proposals a … t investment opportunities at www.themitofund.org . Proposals are accepted on a rolling basis. About UMDF For more than 25 years, The United Mitochondrial Disease Foundation (UMDF) has built a global network of patients, researchers, clinicians, institutions, and industry partners dedicated to fighting mitochondrial disease. Together with the mit
DevelopmentAid For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser .
Khondrion | Our science About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact a new source of energy Targeting the key underlying mechanisms in mitochondrial disease. our approach Khondrion’s development programme is based on decades of academic research, leveraging the increased understanding of the underlying mechanisms of primary mitochondrial disease in combination with the development of new cellular readouts. Khondrion’s drug development strategy is based on counteracting these cellular consequences to stall disease progre
Sonlicromanol in Primary Mitochondrial Disease MELAS Spectrum Disorders - World Mitochondria Society Sonlicromanol in Primary Mitochondrial Disease MELAS Spectrum Disorders Details Published on 18 March 2022 Dr. Jan Smeitink, from Khondrion B.V., Netherlands, will join us this year to present his most recent findings on "Sonlicromanol in Primary Mitochondrial Disease MELAS Spectrum Disorders" . MELAS spectrum disorders caused by the 3243A>G mutation in the MT-TL1 gene lead to hampered oxidative phosphorylation with, as immediate cellular consequences, both reductive and oxidative stress.The … on at the 17th World Congress on Targeting Mitochondria... Read more Best Image Award 2025 Winners Announced We are thrilled to reveal the three winners of the Best Image in Mitochondria Research 2025! ... Read more Mitochondria & Organelle Crosstalk - Rethinking Organelle Crosstalk: Mitochondrial-Derived Vesicles in Peroxisome Biogenesis Presented by Dr. Ayumu Sugiura At the heart of cellular metabolism, mitochondria and peroxisomes play tightly interconnected rol … niversity of Groningen, Netherlands, for receiving the Best Poster Presentation Award at the 15th... Read more Gallbladder Mitochondrial Function as a Predictor of Liver Transplantation Outcomes Wins WMS Best Poster (2) The World Mitochondria Society is excited to announce that Danielius Umbrasas from the Lithuanian University of Health Sci... Read more Nominations for Best Mitochondria Image 2024 1. Never Tear Us Apart By Una Rastovic, The Roger Willi
Khondrion | Movement disorders in children with primary mitochondrial disease About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Movement disorders in children with primary mitochondrial disease Movement, the act or process of moving, the change of place or position or posture, is a complex process under the control of many different parts of the central nervous system including the brain (frontal cortex, basal ganglia, cerebellum) and spinal cord. As brain involvement is common in all ages of primary mitochondrial disease, m
Khondrion | Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease Elevated levels of PGE 2 known to play an essential role in inflammation Inhibition of key enzyme involved in PGE 2 production may offer a potential new treatment approach in protecting COVID-19 patients from severe disease progression and death Company’s le
Encouraging news... - United Mitochondrial Disease Foundation Facebook Log In United Mitochondrial Disease Foundation's Post United Mitochondrial Disease Foundation April 16 · Shared with Public Encouraging news from Khondrion's pivotal Phase 3 KHENERFIN study! Click the link to read the full press release. https://bit.ly/3Ox27O1 All reactions: 62 3 comments 5 shares Like Comment Most relevant Paulien Vogelzang Milestone great news! Thank you for supporting Khondrion’s research! 10w 1 Danette Jett 10w 1 Top fan Joy Krumdiack Awesome news! 10w 1
Khondrion | Our science About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact a new source of energy Targeting the key underlying mechanisms in mitochondrial disease. our approach Khondrion’s development programme is based on decades of academic research, leveraging the increased understanding of the underlying mechanisms of primary mitochondrial disease in combination with the development of new cellular readouts. Khondrion’s drug development strategy is based on counteracting these cellular consequences to stall disease progre
Khondrion | Bringing energy to life About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact bringing energy to life Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. khondrion Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of mitochondrial dysfunction, the company is advancing its wholly owned lead drug candidate sonlicromano
G mutation, a genetically defined population affected by a chronic, progressive, multi-system disorder with high unmet medical need and no approved disease-modifying treatments. Meet KHONDRION BV @ #Sachs_ELSF More Info @ https://lnkd.in/dbteF9r6 #LifeSciences #Biotech #EuropeanBiotech #PharmaIndustry #BiotechConference #InvestmentForum #BioPharma #InvestmentOpportunities #BiotechInvestment #LifeSciencesInnovation #SSLSW"> G mutation, a genetically defined population affected by a chronic, progressive, multi-system disorder with high unmet medical need and no approved disease-modifying treatme
Khondrion | Interview with Herma Renkema, Chief Early Development Officer at Khondrion About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Interview with Herma Renkema, Chief Early Development Officer at Khondrion 1. Tell us about your role as Chief Early Development Officer at Khondrion. There are a lot of different aspects to my role. I help to steer the Khondrion lab as we research the science behind our early-stage rare disease pipeline. I am also responsible for managing the publication of the preclinical and clinical dat … at comes out of our research. I liaise with academic partners and advisors, and apply for the necessary funding, which is crucial to our ongoing research and development. In addition, I monitor our Chemistry, Manufacturing and Controls (CMC) work and manage our work with Contract Research Organizations (CRO) that supply our preclinical trials and experiments. 2. What does a typical day at Khondrion look like for you? My work as Chief Early Development Officer started in June … and to work on a project in cell signaling and virology funded by a Marie Curie fellowship. I then received funding from the Academy of Finland and worked as a junior group leader for a few years. After I moved back to the Netherlands with my family I joined the Center for Systems Biology and Bioenergetics in Nijmegen as a biochemist/cell biologist working on a computational model for cellular energy production. I then took up a senior-Post Doctorate position in the Translati
Khondrion and Seahorse Bioscience in Consortium Awarded Multi-Million Euro Marie Curie Grant for Mitochondrial European Educational Training (MEET) Program - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developme … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Khondrion and Seahorse Bioscience in Consortium Awarded Multi-Million Euro Marie Curie Grant for Mitochondrial European Educational Training (MEET) Program June 1, 2012 | 3 min read Twitter LinkedIn Facebook Email Print NIJMEGEN, Netherlands, May 31, 2012 /PRNewswire/ -- A multi-million euro Marie Curie grant has been a … to a multidisciplinary/multisectorial approach to education. During the 3 year grant period, both Khondrion and Seahorse Bioscience will contribute unique expertise to ensure the success of the shared objectives. Khondrion will optimize their techniques for high-content drug screening, and implement the developed platform in mitochondrial medicine treatment development. "Khondrion is proud to be involved in this international Marie Curie mitochondrial medicine training netwo … ioscience Europe Aps Per Bo Jensen PhD phone;+45-39179876 Head of Biology & Application Development EU email: [email protected] Fruebjergvej 3 www.seahorsebio.com 2100 Copenhagen Denmark SOURCE Seahorse Bioscience, Inc. Twitter LinkedIn Facebook Email Print Europe LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, 2026 · 4 min read · Heather McKenzie Layoff Tra … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
New Patents Granted for Khondrion's Mitochondrial Disease Lead Compound KH176 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search New Patents Granted for Khondrion’s Mitochondrial Disease Lead Compound KH176 November 8, 2017 | 2 min read Twitter LinkedIn Facebook Email Print Khondrion announces today the grant of key patents in the United States of America, Europe and Hong Kong. [08-November-2017] NIJMEGEN, Netherlands, Novemb … on small molecule therapeutics for mitochondrial diseases, announces today the grant of key patents in the United States of America (US 9,388,156 B2), Europe (EP 2872497) and Hong Kong (HK 15110180.2) providing protection for its library of chromanyl-derivatives compounds, including the lead clinical-stage KH176 for the treatment of mitochondrial related disease. The grant of these patents provides the company exclusive rights for KH176 and the other compounds of the library … rtant asset within our IP portfolio," said Jan Smeitink, CEO of Khondrion. "The grant of these patents brings further recognition of the quality of the innovation being carried out by the Khondrion team. We are actively working on the development of our pipeline and additional level of protection of novel products is pending." The patented invention relates to novel chromanyl derivatives compounds among others useful for treating or preventing mitochondrial disorders and dise … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion Presents Phase II KHENERGY Trial Data - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Khondrion Presents Phase II KHENERGY Trial Data November 22, 2017 | 3 min read Twitter LinkedIn Facebook Email Print Khondrion today announced results from its KHENERGY study, a Phase II exploratory trial with oral KH176 in the m.3243A>G multisystem mitochondrial MELAS and MIDD syn … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease April 17, 2026 | 2 min read Twitter LinkedIn Facebook Email Print 52-week Phase 3 trial evaluating the efficacy and safety of sonlicromanol, a novel bra … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders January 10, 2022 | 5 min read Twitter LinkedIn Facebook Email Print Khondrion announced that the last patient has been dosed with sonlicromanol in the K … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders November 22, 2022 | 12 min read Twitter LinkedIn Facebook Email Print Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting … symptoms. The 6-month study, supported by Dutch Patient Foundations and an EFRO Grant (PROJ-00582), is investigating the effect of sonlicromanol in 24 children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to hamper the functioning of one or more oxidative phosphorylation system enzymes and who are suffering from motor symptoms. The study’s primary objective is to evaluate the effect of sonlicromanol on motor funct … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion appoints Jasper Levink as Chief Financial and Business Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Khondrion appoints Jasper Levink as Chief Financial and Business Officer September 11, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Khondrion appoints Jasper Levink as Chief Financial and Business Officer NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutic … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion announces publication in Brain of integrated Phase 2b program demonstrating disease-modifying potential of sonlicromanol in primary mitochondrial disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Khondrion announces publication in Brain of integrated Phase 2b program demonstrating disease-modifying potential of sonlicromanol in primary mitochondrial disease November 8, 2024 | 6 min read Twitter LinkedIn Facebook Email Print NIJMEGEN, the Netherlands – 7 November 2024: Khondrion, a clinical stage b … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease November 14, 2024 | 7 min read Twitter LinkedIn Facebook Email Print Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical t … U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for sonlicromanol. The IND supports the initiation of a pivotal Phase 3 trial in adult patients with PMD due to the m.3243A>G mutation, the most common genetic defect causing PMD. The company expects to initiate the trial in 2025. Sonlicromanol, Khondrion’s lead proprietary drug candidate, is a potentially disease-modifying first-in-class, brain-penetrant redox-modulator with anti-i … k, Chief Executive Officer at Khondrion, said: “ The FDA’s clearance of our IND application for a pivotal Phase 3 trial marks another important milestone for Khondrion’s development of sonlicromanol, a disease-modifying therapy for primary mitochondrial disease that is so desperately needed by PMD patients. We look forward to sharing progress of our clinical program including its expected initiation next year .” Sonlicromanol: one of the most advanced drug candidates in devel … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Khondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News … ed by a significant investment from Khondrion's committed private backers, will fund Wave 1 of the company's pivotal Phase 3 clinical trial of sonlicromanol. Sonlicromanol is a first-in-class small-molecule candidate therapy for m.3243A>G PMD, the most common genetic form of mitochondrial disease. The Phase 3 trial is expected to launch in H2-2025, marking a crucial milestone in Khondrion's mission to deliver the first approved treatment for these devastatin … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Khondrion appoints Herma Renkema as Chief Early Development Officer | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Documents download module Documents download module Document download Dear user, the requested document Attachment_0 is being prepared for download. Once the download is completed you may close this window by clicking on the close button. Close © European Commission 2026 - Documents download module - Version 3.1.1 - Build 20260227-1316
Khondrion BV - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Khondrion BV Holding Company | 2012 | Netherlands | 10-50 | www.khondrion.com Holding Company | 2012 | Netherlands | 10-50 | www.khondrion.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Skin and Musculoskeletal Diseases Endocrinology and Metabolic Disease Other Diseases Small molecule drug Disease domain score A glimpse into the focused therapeutic areas N … 4 weeks after the intake of the last dose of study medication for patients not rolling over into the compassionate use program. Primary safety data and secondary efficacy (endpoint) data will be monitored and reviewed every three months by an independent Data Safety Monitoring Board (DSMB) to evaluate potential risks and benefits. Start Date 09 Aug 2021 Sponsor / Collaborator Khondrion BV [+2] NCT04846036 / Suspended Phase 2 A Randomized Placebo Controlled, Double-blind Phas … ion BV 21 Nov 2024 · www.globenewswire.com UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease 21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondria … e and muscle weakness. With the support and investment by the UMDF via The Mito Fund, we look forward to further progressing our clinical work on sonlicromanol at pace in our upcoming Phase III trial in adult patients with PMD.” Like all investments made by The Mito Fund, the Khondrion consideration went through a rigorous review process by UMDF’s Venture Philanthropy Investment Committee, an advisory group consisting of world-class experts in the areas of mitochondrial disea … rapeutic in a patient-centric manner.” Launched in the summer of 2023, The Mito Fund is UMDF’s most ambitious effort to date to ramp up the development of mitochondrial disease treatments and cures. The fund’s venture philanthropy model is designed not only to financially support the development of the next generation of mitochondrial disease tre
Khondrion | Bringing energy to life About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact bringing energy to life Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. khondrion Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of mitochondrial dysfunction, the company is advancing its wholly owned lead drug candidate sonlicromano
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Khondrion | Khondrion Strengthens Governance with Appointment of Experienced Supervisory Board About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion Strengthens Governance with Appointment of Experienced Supervisory Board Board to Support Execution of Phase 3 Strategy and Long-Term Value Creation NIJMEGEN, The Netherlands –October 6, 2025 – Khondrion , a late-stage clinical biopharmaceutical company developing therapies for primary mitochondrial diseases, today announced the formation of its Supervisory Board, marking
Khondrion | Khondrion Appoints Jasper Levink as New CEO to Lead Next Phase of Growth About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion Appoints Jasper Levink as New CEO to Lead Next Phase of Growth NIJMEGEN, The Netherlands – September 1, 2025 Khondrion , a Phase 3 clinical-stage biopharmaceutical company advancing therapies for primary mitochondrial diseases, today announced the appointment of Jasper Levink as its new Chief Executive Officer. He succeeds Prof. Jan Smeitink , the founder and CEO of Khondrion and a
Khondrion | Khondrion appoints Jasper Levink as Chief Financial and Business Officer About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion appoints Jasper Levink as Chief Financial and Business Officer NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announces the appointment of Jasper Levink MSc, as Chief Financial and Business Officer, effective immediately. Prof. Dr. Jan Smeitink,
Khondrion | Khondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease Government support, alongside private investments, funds first w … ed by a significant investment from Khondrion’s committed private backers, will fund Wave 1 of the company’s pivotal Phase 3 clinical trial of sonlicromanol. Sonlicromanol is a first-in-class small-molecule candidate therapy for m.3243A>G PMD, the most common genetic form of mitochondrial disease. The Phase 3 trial is expected to launch in H2-2025, marking a crucial milestone in Khondrion’s mission to deliver the first approved treatment for these devastating, multisystem
Khondrion | CEO Jan Smeitink on Khondrion’s development program and plans for 2020 About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact CEO Jan Smeitink on Khondrion’s development program and plans for 2020 On Friday 10th January 2020, CEO Jan Smeitink participated in the Annual MitoAction Town Hall Meeting alongside other companies and organisations, sharing an update on Khondrion’s development program and plans for 2020 with the mitochondrial disease community. You can listen to Jan presenting at 1:14:46 or to the full event
Khondrion | EuroHealth Leaders Magazine interviewed Khondrion's CEO Jan Smeitink About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact EuroHealth Leaders Magazine interviewed Khondrion's CEO Jan Smeitink Jan Smeitink: Serving the Mitochondrial Medicine Mission Embarking on the journey of biopharmaceutical innovation demands more than just expertise—it requires an undying commitment to transforming the landscape of healthcare through perseverance and strategic foresight. Leading this dynamic field is Jan Smeitink ,
News - World Mitochondria Society Joomla! provides plenty of flexibility when displaying your Web content. Whether you are using Joomla! for a blog site, news or a Web site for a company, you'll find one or more content styles to showcase your information. You can also change the style of content dynamically depending on your preferences. Joomla! calls how a page is laid out a layout. Use the guide below to understand which layouts are available and how you might use them. Targeting Mitochondria 2023 Venue Details Published on 05 December 2022 The scientific committee is pleased to announc … on at the 17th World Congress on Targeting Mitochondria... Read more Best Image Award 2025 Winners Announced We are thrilled to reveal the three winners of the Best Image in Mitochondria Research 2025! ... Read more Mitochondria & Organelle Crosstalk - Rethinking Organelle Crosstalk: Mitochondrial-Derived Vesicles in Peroxisome Biogenesis Presented by Dr. Ayumu Sugiura At the heart of cellular metabolism, mitochondria and peroxisomes play tightly interconnected rol … niversity of Groningen, Netherlands, for receiving the Best Poster Presentation Award at the 15th... Read more Gallbladder Mitochondrial Function as a Predictor of Liver Transplantation Outcomes Wins WMS Best Poster (2) The World Mitochondria Society is excited to announce that Danielius Umbrasas from the Lithuanian University of Health Sci... Read more Nominations for Best Mitochondria Image 2024 1. Never Tear Us Apart By Una Rastovic, The Roger Willi
#clinicaldevelopment #lifesciences #khondrion #mitochondrialdisease #drugdevelopment #biotechnology #healthcare #innovations #research #progress #eu #collaboration #innovation #funding | Julien Beyrath LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in y
The Drug Development Consultancy Company - 3D-PharmXchange Skip to content Our Solutions Chemistry, Manufacturing, & Control (CMC) Non-Clinical Clinical Regulatory Affairs Leadership Project Management About Us About 3D-PharmXchange Managing Partners News & Insights Blog News Careers Contact Us Navigating Drug Development We provide all core expertise needed to take a drug development program from A to B or A to Z. Learn more » Non-clinical Make use of our scientific know-how, flexibility, and an inherent dedication in non-clinical development. Learn more » CTA/IND Our CMC team’s exp
Khondrion | Khondrion is collaborating globally on its way to market About us KHENERFIN Our Science & Development Our Focus For Patients & Families Working with others News Contact Khondrion is collaborating globally on its way to market In July 2018 Khondrion was awarded €2.3M funding from the highly competitive EU Horizon 2020 SME instrument program to progress clinical development of its lead asset to treat mitochondrial diseases. The Economic Board, a triple helix collaboration between government, knowledge institutions and the business community in the Arnhem-Nijmegen region, with … Nijmegen Radboudumc — was awarded the prestigious H2020 SME Instrument European grant for the testing of a potential new medicine for mitochondrial disorders [ed. metabolic diseases]. CEO Jan Smeitink tells us about the latest developments. There are approximately 250 known genetic deviations that lead to problems with energy metabolism. This can lead to a number of serious health issues. Khondrion is currently testing a group of patients who, because of a certain DNA deviati
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.